Bolt BiotherapeuticsBOLT
13F holders, Q1 2026 (March 31)At the end of Q1 2026, 24 institutions reported holding Bolt Biotherapeutics Inc. (BOLT) in their 13F filings, up 3 from Q4 2025. 3 opened new positions and 2 sold out. The largest holders were Sofinnova Investments, Inc. ($556K), Renaissance Technologies ($312K) and Vivo Capital, LLC ($293K). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Bolt Biotherapeutics Inc.
- CUSIP
- 097702203
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $212K |
| Exits | 2 | $2K |
All 13F filers, Q4 2025 → Q1 2026: 92,457 shares bought and 81,743 shares sold, net +10,714 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 24 holders
| Sofinnova Investments, Inc. | 0.03% | No change | 137,721 | $556K |
| Renaissance Technologies | 0.00% | Add +40.4% | 77,225 | $312K |
| Vivo Capital, LLC | 0.02% | No change | 72,414 | $293K |
| Pivotal bioVenture Partners Investment Advisor LLC | 0.06% | Reduce -55.0% | 42,581 | $172K |
| T3 Companies, LLC | 0.21% | No change | 38,000 | $154K |
| Board of Trustees of The Leland Stanford Junior University | 0.02% | No change | 35,977 | $145K |
| Pfizer Inc | 0.06% | No change | 31,305 | $137K |
| Lynx1 Capital Management LP | 0.02% | New | 30,800 | $124K |
| Nan Fung Group Holdings Ltd | 0.10% | Reduce -49.9% | 29,250 | $118K |
| Geode Capital Management, LLC | 0.00% | Add +53.1% | 28,791 | $116K |
| Nano Cap New Millennium Growth Fund L P | 0.10% | Add +34.1% | 27,500 | $111K |
| Shay Capital LLC | 0.01% | Reduce -2.4% | 14,905 | $60K |
| Susquehanna International Group, LLP | 0.00% | New | 11,657 | $47K |
| Citadel Advisors | 0.00% | New | 10,109 | $41K |
| BlackRock, Inc. | 0.00% | No change | 9,711 | $39K |
| Vanguard Capital Management LLC | 0.00% | — | 7,060 | $29K |
| Morgan Stanley | 0.00% | Add +1.9% | 3,189 | $13K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 3,095 | $13K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +51.2% | 1,093 | $4K |
| UBS Group AG | 0.00% | Add +52.8% | 787 | $3K |
| JPMorgan Chase & Co. | 0.00% | No change | 42 | $179 |
| Vanguard Global Advisers, LLC | 0.00% | — | 24 | $97 |
| SBI Securities Co., Ltd. | 0.00% | No change | 10 | $40 |
| Barclays PLC | 0.00% | No change | 6 | $24 |
"% of holder's portfolio" is BOLT's weight in each manager's 13F, not the share of Bolt Biotherapeutics Inc. the manager owns.